T h cells have long been divided into two subsets, T h 1 and T h 2; however, recently, T h 17 and inducible regulatory T (iTreg) cells were identified as new T h cell subsets. Although T h 1-and T h 2-polarizing cytokines have been shown to suppress T h 17 and iTreg development, transcriptional regulation of T h 17 and iTreg differentiation by cytokines remains to be clarified. In this study, we found that expression of the growth factor independent 1 (Gfi1) gene, which has been implicated in T h 2 development, was repressed in T h 17 and iTreg cells compared with T h 1 and T h 2 lineages. Gfi1 expression was enhanced by the IFN-g/STAT1 and IL-4/STAT6 pathways, whereas it was repressed by the transforming growth factor-b1 stimulation at the promoter level. Over-expression of Gfi1 strongly reduced IL-17A transcription in the EL4 T cell line, as well as in primary T cells. This was due to the blockade of recruitment of retinoid-related orphan receptor gt to the IL-17A promoter. In contrast, IL-17A expression was significantly enhanced in Gfi1-deficient T cells under T h 17-promoting differentiation conditions as compared with wild-type T cells. In contrast, the impacts of Gfi1 in iTregs were not as strong as in T h 17 cells. Taken together, these data strongly suggest that Gfi1 is a negative regulator of T h 17 differentiation, which represents a novel mechanism for the regulation of T h 17 development by cytokines.
Introduction

CD4
+ T h cells play a central role in the immune response. Upon activation by antigens, T h cells undergo distinct developmental pathways, resulting in specialized properties and effector functions. CD4 + T cells are traditionally thought to differentiate into T h 1 and T h 2 cell subsets (1) . T h 1 cells require the transcription factor T-bet, secrete IFN-c and regulate cellular immunity. In contrast, T h 2 cells express GATA3 and c-Maf, produce IL-4, IL-5 and IL-13 and mediate humoral responses (2) (3) (4) .
Recently, a new subset of the polarized T cell subset T h 17 cells, characterized by the production of IL-17A, was identified and found to play an important role in autoimmune diseases, elimination of extracellular bacteria and cancer (5) (6) (7) . The differentiation of T h 17 cells from naive T cells requires transforming growth factor-b1 (TGF-b1) and IL-6 both in vitro and in vivo (8) (9) (10) . In addition, both IL-21 and IL-23 are thought to be critical for the maturation and/or maintenance of T h 17 cells (11) (12) (13) . Recently, the nuclear orphan receptor [retinoid-related orphan receptor ct (RORct)], which is induced by TGF-b1 and IL-6, has been shown to be indispensable for the differentiation of T h 17 cells (14) . Furthermore, we recently reported that RORct was directly involved in IL-17A transcription through binding to IL-17A promoter and that Foxp3 inhibits IL-17A expression through interaction with RORct (15) .
TGF-b1 has also been shown to induce Foxp3, a master transcriptional factor of regulatory T (Treg) cells. Thymusderived naturally occurring regulatory T (nTreg) cells predominantly express Foxp3 and are critically important for immune homeostasis (16) . Likewise, in vitro TGF-b1-induced Treg (iTreg) cells can suppress effector T cell proliferation in vitro as well as in vivo, just as nTreg cells can (17, 18) .
Differentiation of T h cells is regulated by various cytokines and transcription factors. For example, T h 1 is suppressed by IL-4 and T h 2 is suppressed by IFN-c. Moreover, inducible regulatory T (iTreg) is up-regulated by IL-2/STAT5 and downregulated by IFN-c, IL-4 and IL-6/STAT3 (10, (19) (20) (21) . We recently reported that IL-4/STAT6 inhibits TGF-b1-mediated Foxp3 induction through direct binding to the Foxp3 promoter (22) . In the case of T h 17 differentiation, it has been recently reported that T h 17 is negatively regulated by the retinoic acid receptor RAR/RXR and positively regulated by the aryl hydrocarbon receptor AHR (23) (24) (25) . In addition, IFN regulatory factor 4 is required for T h 17 development, while Ets-1 negatively regulates T h 17. T h 17 development is also repressed by various cytokines, such as IL-2, IL-4, IL-27 and IFN-c (26) (27) (28) (29) (30) (31) . These cytokines activate STAT1, STAT5 and STAT6. However, the mechanisms underlying the blockade of T h 17 differentiation by these factors are not entirely clear.
In this study, we found that the expression of growth factor independent 1 (Gfi1) was significantly up-regulated in T h 1 and T h 2 cells, whereas it was repressed in T h 17 and iTreg cells. Gfi1 is a transcriptional repressor with a molecular weight of 47-55 kDa that recognizes the conserved AATC core sequence and binds to DNA through the C-terminal C2H2-type zinc finger domain. Gfi1 has been shown to play a role in granulocyte development, T cell differentiation and macrophage-dependent cytokine production (32) . Recently, it was reported that Gfi1 could be induced in T h 2 cells by IL-4 and STAT6 and that Gfi1 controls T h 2 differentiation through the regulation of GATA3 protein stability (33, 34) . However, the role of Gfi1 in regulating the differentiation of T h 17 and iTreg cells remains unknown. We determined that over-expression of Gfi1 reduced IL-17A transcription in EL4 and primary T cells and inhibited RORct-mediated IL-17A promoter activity by inhibiting RORct activity. Moreover, Gfi1-deficient T cells produced an increased level of IL-17A under T h 17 differentiation conditions, whereas the effect of Gfi1 on TGF-b1-mediated Foxp3 induction was partial. Taken together, our study provides a novel mechanism for regulation of T h 17 development.
Methods
Mice
C57BL/6 mice were purchased from CLEA Japan, Inc. (Tokyo, Japan). The GFI1-deficient mice were described previously (35) . The Smad3-deficient mice were generously provided by Dr Saika Shizuya (Wakayama University School of Medicine) and Dr Flanders (36) . The T cell-specific Smad2-deficient mice will be described elsewhere. All mice were used between the ages of 6 and 12 weeks, and all experiments were approved by the Animal Ethics Committee of Keio University.
Plasmid constructs
PCR was done to generate Gfi1 promoter plasmid by using mouse genomic DNA as a template. In the case of Gfi1 promoter, an ;2 kb fragment corresponding to nucleotides from À1495 to +505 relative to the determined transcriptional staring site of Gfi1 gene was sub-cloned into pGV-basic 2 vector (TOYOINKI). The IL-17A promoter plasmids and the mouse RORct complementary DNA (cDNA)have been described previously (15) . The Foxp3 promoter plasmids have been described previously (22) . The constitutively active transforming growth factorb receptor I (CA-TbRI) was provided by Dr Joan Massagué and has been described previously (37) . Gfi1 cDNA and its mutant form have been described previously (38) .
Luciferase assay
Both transfection into HEK 293T and EL4 cells and the luciferase assay have been described previously (15, 22) . Briefly, HEK 293T cells were seeded on 6-well plates (2 3 10 5 cells per well), cultured for 24 h and transfected with various amounts of expression vector by PEI method (39) . In contrast, EL4 cells (5 3 10 6 cells per well) were transfected by electroporation and then harvested 24 h later. All cells were harvested using 50 ll of lysis buffer. The luciferase assay was performed using a luciferase substrate kit (Promega), and luciferase activity was read with a Packard luminometer and normalized to an internal control, b-galactosidase (b-gal). Western blotting and immunoprecipitation were performed as reported previously (37) .
Naive T cell preparation and differentiation
Single-cell suspensions from the mouse spleens and lymph nodes were negatively depleted by first staining with anti-B220-biotin, anti-CD11b-biotin, anti-CD11c-biotin, antiTer119-biotin, anti-DX5-biotin, anti-CD8a-biotin and anti-CD25-biotin (all from eBioscience) at a 1:125 dilution for 20 min on ice and then incubating with anti-biotin magnetic microbeads (Milteny Biotech) at a 1:20 dilution for 20 min on ice. The depleted fraction was stained with anti-CD62L-FITC, anti-CD25-PE, anti-CD4-PerCP and anti-CD44-APC. Cell sorting was performed using a FACSAria cell sorter (Becton Dickinson) to obtain a pure population of primary CD4 + CD25 À CD62L high CD44 À T cells (typically >98% purity). The CD4
+
CD25
À CD62L high CD44 À T cells (1 3 10 6 cells per well) were cultured at 37°C (5% CO 2 ) in RPMI-1640 (Invitrogen Life Technologies). The medium was supplemented with 10% FCS, 2 mM L-glutamine, 100 U ml À1 penicillin, 100 lg ml À1 streptomycin and 50 lM 2-mercaptoethanol. The cells were stimulated with the plate-bound anti-CD3 antibody (1 lg ml
À1
, clone 145-2C11) and the soluble anti-CD28 antibody (0.5 lg ml À1 , eBioscience). For T h 0 differentiation, the cells were treated with 1 lg ml À1 anti-IFN-c antibody and 1 lg ml À1 anti-IL-4 antibody. For T h 1 differentiation, the cells were treated with 10 ng ml À1 mIL-12p70 (R&D Systems) and 1 lg ml À1 anti-IL-4 antibody. For T h 2 differentiation, the cells were treated with 10 ng ml À1 mIL-4 (PeproTech) and 1 lg ml À1 anti-IFN-c antibody. For iTreg differentiation, the cells were treated with 2 ng ml À1 human TGF-b1 (R&D Systems), 1 lg ml À1 anti-IFN-c antibody and1 lg ml À1 anti-IL-4 antibody. For T h 17 differentiation, the cells were treated with 1 ng ml À1 human TGF-b1, 20 ng ml À1 human IL-6 (R&D Systems), 1 lg ml À1 anti-IFN-c antibody and 1 lg ml À1 anti-IL-4 antibody. Cell surface marker and intracellular cytokine staining were performed as described previously (40) .
Retroviral transduction
Sorted naive CD4
+ CD25 À CD62L high CD44 À T cells were plated in the T h 0 condition starting on day 0. On day 1, fresh retrovirus supernatant was added and the cells were spun at 2500 r.p.m. for 2 h at 35°C. After spin infection, the cells were cultured in iTreg or T h 17 condition medium and harvested on day 4 or 5 for intracellular cytokine staining and real-time PCR analysis.
Reverse transcription-PCR and real-time PCR
The cells were lysed in RNAiso (Takara) for RNA extraction. Reverse transcription (RT)-PCR was performed according to standard procedures. The expression level of GAPDH was evaluated as an internal control. The primer sequences were as follows: GAPDH, 5#-ACCACAGTCCATGCCATCAC-3# and 5#-TCCACCACCCTGTTGCTGTA-3#; HPRT, 5#-TGAAGAGCT ACTGTAATGATCAGTCAAC-3# and 5#-AGCAAGCTTGCAA CCTTAACCA-3#; Gfi1, 5#-AGGAACGCAGCTTTGACTGT-3# and 5#-GATGAGCTTTGCACACTGGA-3#; RORct, 5#-ACCT CCACTGCCAGCTGTGTGCTGTC-3# and 5#-TCATTTCTG-CACTTCTGCATGTAGACTGTCCC-3#; IL-17A 5#-CAGCAGC-GATCATCCCTCAAAG-3# and 5#-CAGGACCAGGATCTCT TGCTG-3# and Foxp3, 5#-CCCAGGAAAGACAGCAACCTT-3# and 5#-TTCTCACAACCAGGCCACTTG-3#. Real-time PCR was performed on cDNA samples using the SYBR Green system (Applied Biosystems). The relative quantitation value is expressed as 2
Àdelta Ct , where delta Ct is the difference between the mean Ct value of triplicates of the sample and of the endogenous HPRT control.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed using ChIP-IT Express (Active Motif) according to the manufacturer's instructions. The cell extracts were immunoprecipitated with polyclonal rabbit anti-T7-tagged antibody (Medical & Biological Laboratories) or monoclonal mouse anti-FLAG-tagged antibody (Sigma) or rabbit antiacetyl-Histone H4 antibody (Upstate) and protein G magnetic beads for 4 h at 4°C. The DNA-histone complexes were incubated for 15 min at 94°C for reverse cross-linking and then treated with protease K. Purified DNA fragments were subjected to real-time PCR, which addressed for the IL-17A promoter region +37 to À205. Real-time PCR was performed using the following primers: 5#-AACTTCTGC CCTTCCCATCT-3# and 5#-GTTTGCGCGTCCTGATCAGC-3#.
Statistical analysis
The Student's paired two-tailed t-test was used. Values of P < 0.05 were considered significant. All error bars shown in this article represent standard deviations.
Results
Gfi1 mRNA is up-regulated in T h 1 and T h 2 cells and downregulated in iTreg and T h 17 cells
We previously reported that loss of suppressor of cytokine signaling 1 (SOCS1) in T h cells causes defective T h 17 differentiation (41) . To identify candidate genes that might be involved in T h 17 suppression, we compared the transcription factors expressed in wild-type (WT) and SOCS1 À/À T cells using DNA microarray analysis. Among the genes up-regulated over twice as much in SOCS1 À/À T cells compared with WT T cells under the T h 17 differentiation conditions, we focused on Gfi1 because it has previously been shown to be involved in T h 2 differentiation (33, 34) .
To determine the pattern of Gfi1 mRNA expression in each T h subset, we examined the expression of Gfi1 mRNA in T cells stimulated with anti-TCR antibody in the presence of cytokines for helper T cell differentiation. As shown in Fig. 1(A) , Gfi1 mRNA was highly expressed in cells exposed to the T h 1 and T h 2 differentiation conditions, whereas the levels were very low in cells exposed to T h 17 and iTreg differentiation conditions. It has been reported that the induction of Gfi1 mRNA is dependent on STAT6 (34) (Fig. 1B) . In contrast, STAT1
À/À T cells expressed high levels of Gfi1 mRNA under T h 2, but not T h 1, differentiation conditions (Fig. 1B) . These data suggest that the induction of Gfi1 expression in T h 1 and T h 2 cells was dependent on STAT1 and STAT6, respectively.
In contrast, Gfi1 mRNA expression decreased in the iTreg-and T h 17-skewed cells (Fig. 1A) . Both iTreg-and T h 17-polarizing media contained TGF-b1. Thus, we speculated that Gfi1 transcription is suppressed by TGF-b1. To test this, we cloned the Gfi1 promoter and performed the reporter analysis in HEK 293T cells. The Gfi1 promoter activity was attenuated by addition of CA-TbRI, suggesting that Gfi1 promoter directly repressed by TGF-b signaling (Fig. 1C) . To determine the downstream-signaling pathway of the TGF-b receptor, we examined Gfi1 expression in T cells from mice lacking Smad2 or Smad3. Unexpectedly, Gfi1 expression was suppressed in T h 17 differentiation condition in both Smad2 À/À and Smad3 À/À T cells (Fig. 1D) . It has been shown that the Smad pathway is non-essential for development of T h 17 (42) . Therefore, Smad-independent TGF-b-signaling pathways could be involved in both Gfi1 repression as well as RORct induction.
Forced expression of Gfi1 suppresses IL-17A expression in HEK 293T and EL4 cells
To investigate the effect of Gfi1 on IL-17A expression, we examined the levels of IL-17A in EL4 cells using RT-PCR. We have previously reported that EL4 cells express IL-17A in response to anti-TCR stimulation because of constitutive expression of RORct (15). Interestingly, forced expression of Gfi1 significantly reduced the expression levels of IL-17A ( Fig. 2A) . However, the expression of RORct was not affected by Gfi1 over-expression. Suppression was not observed when Gfi1III, N-terminal-truncated Gfi1 lacking transcriptional repressor activity, was introduced (data not shown). Thus, these data suggest that Gfi1 specifically inhibits the IL-17A expression.
To determine the suppressive mechanism of IL-17A expression by Gfi1, we investigated whether Gfi1 expression affects RORct-mediated IL-17A transcription using a reporter system described previously (15) . As expected, Gfi1, but not Gfi1III, strongly suppressed RORct-mediated IL-17A promoter activity in a dose-dependent manner in HEK 293T and EL4 cells (Fig. 2B) . On the other hand, Gfi1 did not affect TGF-b-mediated Smad transcriptional activity (Fig. 2C) . Thus, Gfi1 suggested to directly regulate RORct but not Smads.
It has been shown that Gfi1 is a potent transcriptional repressor and recognizes the consensus-binding site, which is defined as AATC (43) . As shown in Fig. 2(D) , there are two Gfi1-binding sites within the IL-17A promoter. Thus, we used a reporter assay and a series of truncation mutants of the IL-17A promoter to examine whether both of the Gfi1-binding sites are essential for the suppression of RORctmediated IL-17A reporter activity by Gfi1. Unexpectedly, Gfi1 still intensively inhibited the RORct-mediated reporter activity of mIL17p(-115)-Luc, which did not contain any Gfi1-binding sites (Fig. 2D) . To investigate further, we used a ChIP assay to examine whether Gfi1 binds to the Gfi1-binding sites within IL-17A promoter. We did not observe any direct binding of Gfi1 to the IL-17A promoter, although the binding of RORct to this promoter was clearly observed with the ChIP assay (Fig. 2E) (15) .
In a prior study, we determined that interaction of Foxp3 with RORct resulted in the suppression of the IL-17A expression by interfering with binding of RORct to the IL-17A promoter (15) . As expected, the ChIP assay showed that forced expression of Gfi1 reduced the binding of RORct to the IL-17A promoter (Fig. 2E) . However, we did not observe a direct association between Gfi1 and RORct by co-immunoprecipitation, whereas the interaction between Foxp3 and RORct was clearly seen (Data not shown).
It has been reported that Gfi1 coordinates epigenetic repression by recruitmenting histone deacetylase to target gene promoters (44) . To test whether histone deacetylase are involved in the suppression of IL-17A transcription by Gfi1, we assayed the ability of Gfi1 to repress transcription in the absence or presence of the histone deacetylase inhibitor TSA. Expectedly, the suppressive effect of Gfi1 overexpression on RORct was abrogated by treatment of TSA in dose-dependent manner (Fig. 2F) .
Taken together, our results indicate that Gfi1 inhibits the RORct-mediated IL-17A transcription by reducing RORct binding to the IL-17A promoter through the recruitment of histone deacetylase, although the detailed molecular mechanism for attenuation of RORct binding by Gfi1 remained to be clarified.
Gfi1 regulates the expression of IL-17A in primary T cells
To determine the function of Gfi1 in IL-17A expression in primary T cells, we first investigated whether Gfi1 expression inhibits T h 17 differentiation in these cells. We used retroviral transduction to deliver Gfi1 to CD4 T cells stimulated under various polarizing conditions. As expected, over-expression of Gfi1 resulted in the repression of IL-17A expression in the transduced (GFP + ) T cells (Fig. 3A) . In contrast, no suppression of IL-17A was observed in cells infected with IRES-GFP control vectors. Furthermore, analysis by real-time PCR confirmed that the forced expression of Gfi1 resulted in reduction of IL-17A transcription (Fig. 3B) . Then, we estimated the acetylated state of histone H4 on the IL-17A promoter in Gfi1-over-expressing primary T h 17 cells.
As expected, over-expression of Gfi1 significantly reduced the acetylation of histone H4 in primary T cells compared with the control vector (Fig. 3C) .
Next, we examined the expression of IL-17A with CD4 + T cells from Gfi1 À/À mice. CD4 + T cells from Gfi1 +/+ or Gfi1 À/À mice were cultured for 3 days with anti-CD3 antibody and anti-CD28 antibody under T h 17-polarizing conditions. As shown in Fig. 3(D) , Gfi1 À/À T cells produced an abnormally high levels of IL-17A protein compared with WT T cells. Under T h 17-polarizing conditions, 52.5% of the differentiated WT T cells stained positive for IL-17A, whereas 84.3% of Gfi1 À/À T cells produced IL-17A (Fig. 3D) . Consistent with the flow cytometry data, high levels of IL-17A expression were observed in Gfi1 À/À T cells by real-time PCR (Fig. 3E) . Together, these data demonstrate that Gfi1 is a potent negative regulator for T h 17 differentiation in primary T cells.
Gfi1 partially reduces the expression of Foxp3 in iTregs
To define the role of Gfi1 on iTreg differentiation, we first measured the levels of Foxp3 mRNA in EL4 cells transfected with Gfi1 using RT-PCR. Forced expression of Gfi1 only partially reduced the expression of Foxp3 (Fig. 4A) . Gfi1 slightly suppressed CREB-mediated Foxp3 promoter activity in a dose-dependent manner in HEK 293T (Fig. 4B) . These data suggest that Gfi1 weakly inhibits the Foxp3 expression.
Next, we investigated the effect of forced expression or deletion of Gfi1 on primary T cells. Similar to EL4 cells, overexpression of Gfi1 resulted in a slight reduction of Foxp3 expression in the transduced (GFP + ) T cells compared with control cells (Fig. 4C) . Then, CD4
+ T cells from Gfi1 À/À mice were cultured for 24 h with anti-CD3 antibody and anti-CD28 antibody under iTreg-polarizing conditions. As shown in Fig. 4(D) , Foxp3 mRNA levels in Gfi1 À/À T cells were higher than those in WT T cells (Fig. 4D) . Together, these data indicate that Gfi1 could suppress the iTreg differentiation; however, its effect on iTreg was not as drastic as in T h 17.
Discussion
In this study, we found that Gfi1 negatively regulates T h 17 differentiation by repressing RORct activity. Since Gfi1 expression is induced by the IFN-c/STAT1 or IL-4/STAT6-signaling pathways, Gfi1 could provide a mechanism to suppress IL-17A expression through the presence of IFN-c and IL-4. Indeed, we observed that the addition of IFN-c or IL-4 to T h 17 differentiation conditions (media supplemented with TGF-b1 and IL-6) increased the expression of Gfi1 in whole cultured cells (data not shown).
Alternatively, Gfi1 may ensure low levels of IL-17A expression in T h 1 or T h 2 cells. We found that the expression of Gfi1 mRNA is mediated by the TGF-b1 stimulation. Thus, Gfi1 repression by TGF-b1 could be essential for the expression of IL-17A in T h 17 cells. T h 17 cells express not only IL-17A but also IL-17F and IL-22, and Gfi1 may affect their expression as well. Further study is necessary to ascertain the role of Gfi1 in regulation of T h 17-related genes.
Previously, we found that T h 17 development was severely impaired in SOCS1-deficient T cells. We showed that this is due to strong activation of STAT1, which leads to suppression of STAT3 and activation of Smad (41) . We noticed high levels of expression of Gfi1 in SOCS1 À/À T cells, which can be explained by increased STAT1 activity or decreased Smad activity.
It has been shown that Gfi1 acts as a transcriptional repressor through the interaction of a unique N-terminal SNAG domain with various proteins (45) . Thus, we hypothesized that Gfi1 inhibits the RORct function by physical interaction with RORct at the N-terminal region. To test this hypothesis, we investigated whether Gfi1 interferes with RORct binding at the RORct-binding site within the IL-17A promoter. As expected, Gfi1 inhibits the RORct-mediated IL-17A transcription by reducing RORct binding to the IL-17A promoter. Unexpectedly, we did not observe a direct association between Gfi1 and RORct by co-immunoprecipitation (Data not shown). However, we could not rule out the possibility that Gfi1 weakly associates with RORct or binds indirectly through other factors. We found that the suppressive function of Gfi1 was abrogated by treatment of TSA (Fig. 2F) and that Gfi1 over-expression suppressed histone acetylation on the IL-17A promoter in primary T cells (Fig. 3C) . It has been reported that Gfi1 recruits histone deacetylases to target gene promoters (44) . Thus, Gfi1 is most likely to repress RORct-mediated IL-17A transcription by enhancing histone deacetylation, although detailed molecular mechanism for attenuation of RORct binding by Gfi1 remains to be clarified.
Alternatively, Ets1 may be involved in Gfi1-mediated suppression. Previous studies have demonstrated that Ets1 is a negative regulator of T h 17 differentiation (46) . In addition, it has been shown that the interaction between Ets1 and Gfi1 transcription factors cooperatively facilitates the repression of their target gene expression (47) . Identifying the target genes or protein interactions of Gfi1 will help us understand this observation.
Recently, Zhu et al. (48) reported about the role of Gfi1 in regulating the differentiation of T h 17 and iTreg differentiation. They demonstrated that Gfi1 significantly inhibited IL-17A production, although it had a minimal effect on the expression of Foxp3 and RORct. Our data are consistent with the results by Zhu et al. In addition, we found that Gfi1 suppressed the RORct-mediated IL-17A transcription by reducing RORct binding to the IL-17A promoter through the recruitment of histone deacetylase.
In conclusion, we propose that Gfi1 is a negative regulator of T h 17 differentiation, which provides a novel mechanism for regulation of T h cell development. This suggests that Gfi1 could be a promising therapeutic target for autoimmune disease and allergy. 
